Schwendicke Falk, Brouwer Fredrik, Stolpe Michael
Department of Operative and Preventive Dentistry, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Department of Operative and Preventive Dentistry, Charité-Universitätsmedizin Berlin, Berlin, Germany.
J Endod. 2015 Dec;41(12):1969-74. doi: 10.1016/j.joen.2015.08.019. Epub 2015 Oct 2.
Recent evidence finds mineral trioxide aggregate (MTA) more effective than calcium hydroxide (CH) for direct pulp capping (DPC). The present study assessed the cost-effectiveness of MTA versus CH for DPC using a model-based simulation approach.
A mixed public/private payer perspective in the context of German health care was adopted. We modeled a permanent molar with a vital asymptomatic, exposed pulp treated via DPC with either MTA or CH. The tooth was followed over the lifetime of a 20-year-old patient using Markov models. Transition probabilities were obtained from systematically and nonsystematically collected data. The primary health outcome was tooth retention time. Costs for DPC were estimated via microcosting. Required personnel time for application was estimated using a survey among German specialized and general dentists. Material expenses were calculated based on market prices in 2015. All other costs were derived from public and private item fee catalogues. Uncertainty was introduced via probabilistic and univariate sensitivity analyses.
DPC using MTA was both more effective and less costly (52 years retention, lifetime costs = 1368 Euro) than CH (49 years, 1527 Euro). Regardless of a payer's willingness to pay, DPC with MTA had the higher probability of being cost-effective. The identified ranking was not affected by parameter or structural uncertainty or heterogeneity.
MTA was more cost-effective than CH for DPC despite higher initial treatment costs because expensive retreatments were avoided. Our estimates apply only on the basis of current evidence and within the chosen health care setting. From a payer's perspective, MTA should be used for DPC.
最近有证据表明,在直接盖髓术(DPC)中,矿物三氧化物凝聚体(MTA)比氢氧化钙(CH)更有效。本研究采用基于模型的模拟方法评估了MTA与CH用于DPC的成本效益。
采用德国医疗保健背景下的公共/私人混合支付者视角。我们构建了一个模型,模拟一名20岁患者的一颗有活力、无症状且牙髓暴露的恒磨牙,分别用MTA或CH进行DPC治疗。使用马尔可夫模型对该牙齿在患者20年的寿命期内进行跟踪。转移概率来自系统收集和非系统收集的数据。主要健康结局是牙齿保留时间。通过微观成本核算估计DPC的成本。通过对德国专科和全科牙医进行调查,估计应用所需的人员时间。材料费用根据2015年的市场价格计算。所有其他成本来自公共和私人项目费用目录。通过概率和单变量敏感性分析引入不确定性。
使用MTA进行DPC比使用CH更有效且成本更低(保留时间52年,终生成本 = 1368欧元)(CH为49年,1527欧元)。无论支付者的支付意愿如何,使用MTA进行DPC具有更高的成本效益概率。确定的排名不受参数或结构不确定性或异质性的影响。
尽管MTA的初始治疗成本较高,但在DPC中它比CH更具成本效益,因为避免了昂贵的再治疗。我们的估计仅基于当前证据并在所选择的医疗保健环境内适用。从支付者的角度来看,MTA应用于DPC。